BR112022013796A2 - Administração repetida de di-hidroergotamina para o tratamento de dores de cabeça do tipo enxaqueca frequentes - Google Patents

Administração repetida de di-hidroergotamina para o tratamento de dores de cabeça do tipo enxaqueca frequentes

Info

Publication number
BR112022013796A2
BR112022013796A2 BR112022013796A BR112022013796A BR112022013796A2 BR 112022013796 A2 BR112022013796 A2 BR 112022013796A2 BR 112022013796 A BR112022013796 A BR 112022013796A BR 112022013796 A BR112022013796 A BR 112022013796A BR 112022013796 A2 BR112022013796 A2 BR 112022013796A2
Authority
BR
Brazil
Prior art keywords
dihydroergotamine
migraine
treatment
frequent
repeated administration
Prior art date
Application number
BR112022013796A
Other languages
English (en)
Inventor
D Hoekman John
H Satterly Kelsey
B Shrewsbury Stephen
Youmans Scott
fuller Christopher
Original Assignee
Impel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impel Pharmaceuticals Inc filed Critical Impel Pharmaceuticals Inc
Publication of BR112022013796A2 publication Critical patent/BR112022013796A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Abstract

ADMINISTRAÇÃO REPETIDA DE DI-HIDROERGOTAMINA PARA O TRATAMENTO DE DORES DE CABEÇA DO TIPO ENXAQUECA FREQUENTES. A presente invenção se refere a métodos para a redução da frequência de ataques de enxaqueca em um indivíduo que tem dores de cabeça do tipo enxaqueca frequentes com ou sem aura. Os métodos compreendem a administração intranasal ao indivíduo de uma composição farmacêutica compreendendo di-hidroergotamina (DHE) ou o sal da mesma em um programa de dose repetida, em que cada administração intranasal é aplicada por um dispositivo de administração de dose medida, atuado manualmente, acionado por propulsor, e em que o programa é um programa intermitente crônico no qual cada uma das administrações repetidas é realizada enquanto o indivíduo está vivenciando uma dor de cabeça do tipo enxaqueca.
BR112022013796A 2020-01-14 2021-01-13 Administração repetida de di-hidroergotamina para o tratamento de dores de cabeça do tipo enxaqueca frequentes BR112022013796A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062961076P 2020-01-14 2020-01-14
PCT/US2021/013282 WO2021146318A1 (en) 2020-01-14 2021-01-13 Repeated administration of dihydroergotamine for treatment of frequent migraine headaches

Publications (1)

Publication Number Publication Date
BR112022013796A2 true BR112022013796A2 (pt) 2022-09-20

Family

ID=76864247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013796A BR112022013796A2 (pt) 2020-01-14 2021-01-13 Administração repetida de di-hidroergotamina para o tratamento de dores de cabeça do tipo enxaqueca frequentes

Country Status (9)

Country Link
US (1) US20210236485A1 (pt)
EP (1) EP4090331A4 (pt)
JP (1) JP2023511547A (pt)
KR (1) KR20220129586A (pt)
CN (1) CN115279371A (pt)
AU (1) AU2021207626A1 (pt)
BR (1) BR112022013796A2 (pt)
CA (1) CA3167555A1 (pt)
WO (1) WO2021146318A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511186A (zh) * 2005-04-04 2009-08-19 卫材R&D管理有限公司 用于头痛的二氢吡啶化合物和组合物
EP2425819A1 (en) * 2007-02-11 2012-03-07 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
JP6937368B2 (ja) * 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
US20190209463A1 (en) * 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of dihydroergotamine by precision olfactory device

Also Published As

Publication number Publication date
CN115279371A (zh) 2022-11-01
AU2021207626A1 (en) 2022-09-01
WO2021146318A1 (en) 2021-07-22
EP4090331A1 (en) 2022-11-23
AU2021207626A8 (en) 2022-10-27
JP2023511547A (ja) 2023-03-20
CA3167555A1 (en) 2021-07-22
EP4090331A4 (en) 2023-12-27
US20210236485A1 (en) 2021-08-05
KR20220129586A (ko) 2022-09-23

Similar Documents

Publication Publication Date Title
ECSP17077930A (es) Métodos y kits para tratar la depresión
BR112015024869A8 (pt) uso de um agente terapêutico e/ou de diôxido de carbono para tratar um paciente e aparelhos e métodos para tratar terapeuticamente um paciente
BR112018011281A2 (pt) composição de tabaco, dispositivo para geração de um aerossol inalável, artigo para fumar para uso com um aparelho que aquece material fumável e cartucho para uso com um aparelho que aquece material fumável
BR112017025166A2 (pt) métodos de condicionar pacientes para terapia de células t
BR112018076001A2 (pt) métodos de tratamento de câncer de mama ar+
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
MX2016004316A (es) Inhalador de polvo seco.
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112018011266A2 (pt) ?composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica?
BR112017015353A2 (pt) inalador de pó seco que compreende propionato de fruticasona e xinafoato de salmeterol
PH12019501408A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
BR112018072988A2 (pt) irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula
BR112019003753A2 (pt) sistema e método para terapia médica controlada
PH12019501458A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
CR20190125A (es) Combinación de agonistas de fxr
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112022013796A2 (pt) Administração repetida de di-hidroergotamina para o tratamento de dores de cabeça do tipo enxaqueca frequentes
BR112015018120A2 (pt) partículas cristalinas multicomponentes para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado, métodos de tratamento de uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, de preparação das partículas
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX2019005160A (es) Formulacion farmaceutica.
BR112017014861A2 (pt) ?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar?
BR112016029926A2 (pt) administração nasal
PL423673A1 (pl) Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
BR112014015329A8 (pt) dispositivos de liberação de droga transmucosa para uso em alívio de dor crônica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]